Hormone replacement therapy in postmenopausal women

American Journal of Surgery

Volumn 188, Issue 2, 2004, Pages 136-149

  Staren, Edgar D ^a   Omer, Shuab ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Cancer; Coronary artery disease; Estrogen; Hormone replacement therapy; Hot flashes; Menopause

Indexed keywords

ALPHA TOCOPHEROL; CIMICIFUGA RACEMOSA EXTRACT; CLONIDINE; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; FLUOXETINE; GABAPENTIN; GESTAGEN; GINSENG EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOFLAVONE; MEDROXYPROGESTERONE ACETATE; PAROXETINE; PHOSPHONIC ACID DERIVATIVE; PROGESTERONE; RALOXIFENE; SEROTONIN UPTAKE INHIBITOR; SEX HORMONE; TAMOXIFEN; VENLAFAXINE; VITAMIN D;

AGE; BONE DENSITY; BONE MINERAL; BREAST CANCER; CANCER RISK; CARDIOVASCULAR RISK; CHOLECYSTITIS; CLINICAL TRIAL; COLORECTAL CANCER; CORONARY ARTERY DISEASE; ESOPHAGITIS; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HIP FRACTURE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYSTERECTOMY; LUNG EMBOLISM; MENOPAUSAL SYNDROME; MORTALITY; OBSERVATION; OVARY CANCER; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SCIENCE; SIDE EFFECT; STROKE; UROGENITAL TRACT DISEASE; VENOUS THROMBOEMBOLISM;

BREAST NEOPLASMS; C-REACTIVE PROTEIN; CEREBROVASCULAR ACCIDENT; CHOLECYSTITIS; CHRONIC DISEASE; CORONARY DISEASE; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; VENOUS THROMBOSIS; WOMEN'S HEALTH;

EID: 3142683004     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2003.12.063     Document Type: Review

References (136)

1. Keating N., Cleary P., Rossi A., et al. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med. 130:1999;545-553
2. Kreling D., Mott D., Wiederholt J., et al. Prescription Drug Trends A Chart Book Update. 2001;Kaiser Family Foundation, Menlo Park, CA
3. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Writing Group For The Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy post menopausal women principal results from the Women's Health Initiative randomized controlled trial. JAMA. 288:2002;321-333
4. Barrett-Connor E. Postmenopausal estrogen and prevention bias. Ann Intern Med. 115:1991;455-456
5. Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. N Engl J Med. 303:1980;1038-1041
6. Horwitz R.I., Viscoli C.M., Berkman L., et al. Treatment adherence and risk of death after myocardial infarction. Lancet. 336:1990;542-545
7. Petitti D.B. Coronary heart disease and estrogen replacement therapy. Can compliance bias explain the results of observational studies? Ann Epidemiol. 4:1994;115-118
8. Schairer C., Lubin J., Troisi R., et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. 283:2000;485-491
9. Ross R.K., Paganini-Hill A., Wan P.C., Pike M.C. Effect of hormone replacement therapy on breast cancer risk estrogen versus estrogen plus progestin. J Natl Cancer Inst. 92:2000;328-332
10. Chen C.L., Weiss N.S., Newcomb P., et al. Hormone replacement therapy in relation to breast cancer. JAMA. 287:2002;734-741
11. Enserink M. Epidemiology. Despite safety concerns, U.K. hormone study to proceed. Science. 297:2002;492
12. Enserink M. Women's health. U.K. hormone trial to pause for review. Science. 297:2002;755-757
13. United States Preventive Services Task Force. Hormone replacement therapy for primary prevention of chronic conditions. Recommendations and rationale. Available at: http://www.ahrq.gov/clinic/3rduspstf/hrt/hrtrr.htm. Accessed July 14, 2003
14. Grady D., Rubin S.N., Petitti D.B., et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 117:1992;1016-1037
15. Grodstein F., Manson J.E., Colditz G.A., et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 133:2000;933-941
16. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease factors in postmenopausal women. JAMA. 273:1995;199-208
17. Mendelsohn M.E., Karas R.H. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 340:1999;1801-1811
18. Adams M.R., Kaplan J.R., Manuck S.B., et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Atherosclerosis. 10:1990;1051-1057
19. Sullivan J.M., Vander Zwaag R., Hughes J.P., et al. Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. Arch Intern Med. 150:1990;2257-2562
20. Sullivan J.M., El-Zeky F., Vander Zwaag R., Ramanathan K.B. Effect on survival of estrogen replacement therapy after coronary artery bypass grafting. Am J Cardiol. 79:1997;847-850
21. Grodstein F., Stampfer M.J., Manson J.E., et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 335:1996;453-461
22. Rosenberg L., Palmer J.R., Shapiro S. A case-control study of myocardial infarction in relation to use of estrogen supplements. Am J Epidemiol. 137:1993;54-63
23. Grady D., Herrington D., Bittner V., et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy Heart and Estrogen/Progestin Replacement Study follow up (HERS II). JAMA. 288:2002;49-57
24. Herrington D.M., Reboussin D.M., Brosnihan K.B., et al. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med. 343:2000;522-529
25. Alexander K.P., Newby L.K., Hellkamp A.S., et al. Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow up. J Am Coll Cardiol. 38:2001;1-7
26. Grodstein F., Manson J.E., Stampfer M.J. Postmenopausal hormone use and secondary prevention of coronary events in the Nurses Health Study a prospective observational study. Ann Intern Med. 135:2001;1-8
27. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 280:1998;605-613
28. Lanfant C. Preliminary Trends in the Women's Health Initiative (press release). 2000;NHLBI Communications Office, Bethesda, MD
29. National Heart, Lung and Blood Institute. Women's Health Initiative hormone replacement therapy study fact sheets. Available at: http://www.nhlbi.nih.gov/health/women/pht_facts.htm#whi. Accessed July 14, 2003
30. Viscoli C.M., Brass L.M., Kernan W.N., et al. A clinical trial of estrogen replacement therapy after ischemic stroke. N Engl J Med. 345:2001;1243-1249
31. Coronary Drug Project Research Group. The Coronary Drug Project findings leading to discontinuation of the 2.5/mg day estrogen group. JAMA. 226:1973;652-657
32. Psaty B.M., Smith N.L., Lemaitre R.N., et al. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA. 285:2001;906-913
33. Hulley S., Furberg C., Barrett-Connor E., et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 288:2002;58-66
34. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease factors in postmenopausal women. Published erratum. JAMA. 274:1995;1676
35. Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy. A report from the Boston Collaborative Drug Surveillance Program, Boston University Medical Center. N Engl J Med 1974;290:15-9
36. Daly E., Vessey M.P., Hawkins M.M., et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 348:1996;977-980
37. Daly E., Vessey M.P., Painter R., Hawkins M.M. Case-control study of venous thromboembolism risk in users of hormone replacement therapy (letter). Lancet. 348:1996;1027
38. Perez-Gutthann S., Garcia-Rodriguez L.A., Castellsague J., Duque Oliart A. Hormone replacement therapy and risk of venous thromboembolism population based case-control study. Br Med J. 314:1997;796-800
39. Varas-Lorenzo C., Garcia Rodriguez L.A., Cattaruzzi C., et al. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism. A population-based study in southern Europe. Am J Epidemiol. 147:1998;387-390
40. Hoibraaten E., Abdelnoor M., Sandset P.M. Hormone replacement therapy with estradiol and risk of venous thromboembolism. A population-based case-control study. Thromb Haemost. 82:1999;1218-1221
41. Devor M., Barrett-Connor E., Renvall M. Estrogen replacement therapy and the risk of venous thrombosis. Am J Med. 92:1992;275-282
42. Jick H., Derby L.E., Myers M.W. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet. 348:1996;981-983
43. Grodstein F., Stampfer M.J., Goldhaber S.Z., et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 348:1996;983-987
44. Suissa S., Blais L., Spitzer W.O. First time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception. 56:1997;144-146
45. Herrington D.M., Klein K.P. Cardiovascular trials of estrogen replacement therapy. Ann NY Acad Sci. 949:2001;153-162
46. Ross R.K., Pike M.C., Henderson B.E., et al. Stroke prevention and oestrogen replacement therapy. Lancet. 1:1989;505
47. Finucane F.F., Madans J.H., Bush T.L., et al. Decreased risk of stroke among postmenopausal hormone users. Results from a national cohort. Arch Intern Med. 153:1993;73-79
48. Murphy D.D., Cole N.B., Greenberger V., Segal M. Estradiol increases dendritic density by reducing GABA neurotransmission in hippocampal neurons. J Neurosci. 18:1998;2550-2559
49. Cushman M., Legault C., Barrett-Connor E., et al. Effect of postmenopausal hormones on inflammation sensitive proteins. Postmenopausal Estrogen/Progestin Interventions study. Circulation. 100:1999;717-722
50. Vehkavaara S., Silveira A., Hakala-Ala-Pietila T., et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost. 85:2001;619-625
51. Koukoulis G.N. Hormone replacement therapy and breast cancer risk. Ann N Y Acad Sci. 900:2000;422-428
52. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet. 350:1997;1047-1059
53. Clemons M., Goss P. Estrogen and the risk of breast cancer. N Engl J Med. 344:2001;276-285
54. Cauley J.A., Lucas F.L., Kuller L.H., et al. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Ann Intern Med. 130:1999;270-277
55. Cauley J., Lucas F.L., Kuller L.H., et al. Bone mineral density and risk of breast cancer in older women the study of osteoporotic fractures. JAMA. 276:1996;1404-1408
56. de Lignieres B., de Vathaire F., Fournier S., et al. Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women. Climacteric. 5:2002;332-340
57. Diamanti-Kandarakis E., Sykiotis G.P., Papavassiliou A.G. Selective modulation of postmenopausal women cutting the Gordian knot of hormone replacement therapy with breast carcinoma. Cancer. 97:2003;12-20
58. Grady D, Ernster VL. Does postmenopausal hormone therapy cause breast cancer? Am J Epidemiol 1991;134:1396-1401; discussion of Kaufman DW, Palmer JR, de Mouzon J, et al. Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study. Am J Epidemiol 1991;134:1375-85
59. Grady D, Ernster VL. Does postmenopausal hormone therapy cause breast cancer? Am J Epidemiol 1991;134:1396-1401; discussion of Kaufman DW, Palmer JR, de Mouzon J, et al. Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study. Am J Epidemiol 1991;134:1375-85
60. Holli K., Isola J., Cuzick J. Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol. 16:1998;3115-3120
61. Gajdos C., Tarter P.T., Babinszki A. Breast cancer diagnosed during hormone replacement therapy. Obstet Gynecol. 95:2000;513-518
62. Cramer D.W., Welch W.R. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst. 71:1983;717-721
63. Hartge P., Hoover R., McGowan L., et al. Menopause and ovarian cancer. Am J Epidemiol. 127:1988;990-998
64. Harris R., Whittemore A.S., Itnyre J. Characteristics relating to ovarian cancer risk collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol. 136:1992;1204-1211
65. Booth M., Beral V., Smith P. Risk factors for ovarian cancer a case control study. Br J Cancer. 60:1989;592-598
66. Cramer D.W., Hutchison G.B., Welch W.R., et al. Determinants of ovarian cancer risks. I. Reproductive experiences and family history. J Natl Cancer Inst. 71:1983;711-716
67. Kaufman D.W., Kelly J.P., Welch W.R., et al. Noncontraceptive estrogen use and epithelial ovarian cancer. Am J Epidemiol. 130:1989;1142-1151
68. Negri E., Tzonou A., Beral V., et al. Hormonal therapy for menopause and ovarian cancer in a collaborative re-analysis of European studies. Int J Cancer. 80:1999;848-851
69. Purdie D.M., Bain C.J., Siskind V., et al. Hormone replacement therapy and risk of epithelial ovarian cancer. Br J Cancer. 81:1999;559-563
70. Rodriguez C., Patel A.V., Calle E.E., et al. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA. 285:2001;1460-1465
71. Lacey J.V. Jr, Mink P.J., Lubin J.H., et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA. 288:2002;334-341
72. Riman T., Dickman P.W., Nilsson S., et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst. 94:2002;497-504
73. Larsson-Cohn U., Johansson E.D., Kagedal B., Wallentin L. Serum FSH, LH and oestrone levels in postmenopausal patients on oestrogen replacement therapy. Br J Obstet Gynecol. 85:1978;367-372
74. Helzlsouer K.J., Alberg A.J., Gordon G.B., et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA. 274:1995;1926-1930
75. Young R.C., Perez C.A., Hoskins W.J. Cancer of the ovary. Devita V., Helman S., Rosenberg S. Cancer Principles and Practice of Oncology. 4th ed :1993;1226-1263 Lippincott, Philadelphia, PA
76. Chien C.-H., Wang F.-F., Hamilton T.C. Transcriptional activation of C-myc proto-oncogene by estrogen in human ovarian cancer cells. Mol Cell Endocrinol. 99:1994;11-19
77. Markman M., Isemingar K.A., Hatch K.D., et al. Tamoxifen in platinum-refractory ovarian cancer a Gynecologic Oncology Group Ancillary Report. Gynecol Oncol. 62:1996;4-6
78. Nanda K., Bastian L.A., Hasselblad V., Simel D.L. Hormone replacement therapy and the risk of colorectal cancer a meta-analysis. Obstet Gynecol. 93:1999;880-888
79. Grodstein F., Newcomb P.A., Stampfer M.G. Postmenopausal hormone therapy and the risk of colorectal cancer a review and meta-analysis. Am J Med. 106:1999;574-582
80. Grady D., Gebretsadik T., Kerlikowske K., et al. Hormone replacement therapy and endometrial cancer risk a meta-analysis. Obstet Gynecol. 85:1995;304-313
81. Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 275:1996;370-375
82. Persson I., Adami H.O., Bergkvist L., et al. Risk of endometrial cancer after treatment with estrogen alone or in conjunction with proestrogens results of a prospective study. Br Med J. 298:1989;147-151
83. Sturdee D., Barlow D.H., Ulrich L.G., et al. Is the timing of withdrawal bleeding a guide to endometrial safety during sequential oestrogen-progestagen replacement therapy? Lancet. 334:1994;979-982
84. Grodstein F., Colditz G.A., Stampfer M.J. Postmenopausal hormone use and cholecystectomy in a large prospective study. Obstet Gynecol. 83:1994;5-11
85. Petitti D.B., Sidney S., Perlman J. Increased risk of cholecystectomy in users of supplemental estrogen. Gastroenterology. 94:1988;91-95
86. Kakar F., Weiss N.S., Strite S.A. Non-contraceptive estrogen use and the risk of gallstone disease in women. Am J Public Health. 78:1988;564-566
87. Everson R.B., Byar D.P., Bishoff A.J. Estrogen predisposes to cholecystectomy but not to stones. Gastroenterology. 82:1982;4-8
88. Mamdani M.M., Tu K., van Walraven C., et al. Postmenopausal estrogen replacement therapy and increased rates of cholecystectomy and appendectomy. CMAJ. 162:2000;1421-1424
89. Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 276:1996;1389-1396
90. Rosen C.J. Treatment of postmenopausal osteoporosis an evidence-based approach. Rev Endocr Metab Disord. 2:2001;35-43
91. MacLennan A., Lester S., Moore V. Oral estrogen replacement therapy versus placebo for hot flushes a systematic review. Climacteric. 4:2001;58-74
92. Komulainen M.H., Kroger H., Tuppurainen M.T., et al. HRT and Vit D in the prevention of non-vertebral fractures in postmenopausal women a 5 year randomized trial. Maturitas. 31:1998;45-54
93. Cauley J.A., Black D.M., Barrett-Connor E., et al. Effects of hormone replacement therapy on clinical fractures and height loss the Heart and Estrogen/Progestin Replacement Study (HERS). Am J Med. 110:2001;442-450
94. Cummings S.R., Black D.M., Thompson D.E., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures results from the Fracture Intervention Trial. JAMA. 280:1998;2077-2082
95. Harris S.T., Watts N.B., Genant H.K., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA. 282:1999;1344-1352
96. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 348:1996;1535-1541
97. McClung M.R., Geusens P., Miller P.D., et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 344:2001;333-340
98. Ettinger B., Pressman A., Schein J. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manag Care. 4:1998;1377-1382
99. Ettinger B., Black D.M., Mitlak D.H., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA. 282:1999;637-645
100. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 340:1999;115-126
101. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 342:2000;836-843
102. van Baal W.M., Emeis J.J., Kenemans P., et al. Short-term hormone replacement therapy reduced plasma levels of soluble adhesion molecules. Eur J Clin Invest. 29:1999;913-921
103. Ridker P.M., Hennekens C.H., Rafai N., et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation. 100:1999;713-716
104. van Baal W.M., Kenemans P., van der Moren M.J., et al. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women. Thromb Haemost. 81:1999;925-928
105. Vanhulle G, Demol P. A double blind study into the influence of estriol on a number of psychological tests in postmenopausal women. In: Van Keep PA, Greenblatt RB, Albeaux-Femet H, editors. Consensus on Menopause Research. Baltimore, MD: University Park Press; p. 94-9, 1977
106. Sherwin B.B. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology. 13:1988;345-357
107. Saletu B., Brandstatter N., Metka M., et al. Double-blind, placebo-controlled, hormonal, syndromal and EEG mapping studies with transdermal oestradiol therapy in menopausal depression. Psychopharmacology (Berl). 22:1995;321-329
108. Sherwin B.B., Gelfand M.M. Sex steroids and affect in the surgical menopause a double-blind, cross-over study. Psychoneuroendocrinology. 10:1985;325-335
109. Greendale G.A., Reboussin B.A., Hogan P., et al. Symptom relief and side effects of postmenopausal hormones results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol. 92:1998;982-988
110. Hlatky M.A., Boothroyd D., Vittinghoff E., et al. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA. 287:2002;591-597
111. Collins P., Webb C. Estrogen hits the surface. Nat Med. 5:1999;1130-1131
112. Stearns V., Ullmer L., Lopez J.F., et al. Hot flushes. Lance. 360:2002;1851-1861
113. Loprinzi C.L., Michalak J.C., Quella S.K., et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med. 331:1994;347-352
114. Pandya K.J., Raubertas R.F., Flynn P.J., et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med. 132:2000;78-93
115. Lobo R.A., Whitehead M.I. Is low-dose hormone replacement therapy for postmenopausal women efficacious and desirable? Climacteric. 4:2001;110-119
116. Utian W.H., Shoupe D., Bachmann G., et al. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 75:2001;1065-1079
117. Utian W.H., Schiff I. NAMS-Gallup survey on women's knowledge, information sources, and attitudes to menopause and hormone replacement therapy. Menopause. 1:1994;39-48
118. Davis S.R. Phytoestrogen therapy for menopausal symptoms? Br Med J. 323:2001;354-355
119. Fisher B., Costantino J., Wickerham D., et al. Tamoxifen for prevention of breast cancer report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 90:1998;1371-1388
120. Cummings S.R., Eckert S., Krueger K.A., et al. The effect of raloxifene on risk of breast cancer in postmenopausal women results from the MORE randomized trial. JAMA. 281:1999;2189-2197
121. Fisher B., Costantino J.P., Redmond C.K., et al. Endometrial cancer in tamoxifen-treated breast cancer patients findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 86:1994;527-537
122. Barrett-Connor E., Grady D., Sashegyi A., et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA. 287:2002;847-857
123. Fisher B., Costantino J., Redmond C., et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor-positive tumor. N Engl J Med. 320:1989;479-484
124. Fisher B., Dignam J., Bryant J., et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 88:1996;1529-1542
125. Santen R.J. Long-term tamoxifen therapy can an antagonist become an agonist? J Clin Endocrinol Metab. 81:1996;2027-2029
126. Ries LAG, Eisner MP, Kosary CL, editors. SEER Cancer Statistics Review 1973-1998. Bethesda, MD: United States Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute; 2001
127. Mosca L., Collins P., Herrington D.M., et al. Hormone replacement therapy and cardiovascular disease a statement for healthcare professionals from the American Heart Association. Circulation. 104:2001;499-503
128. Simon J.A., Hsia J., Cauley J.A., et al. Postmenopausal hormone therapy and risk of stroke. The Heart and Estrogen/progestin Replacement Study (HERS). Circulation. 103:2001;638-642
129. Santoro N.F., Col N.F., Eckman M.H., et al. Therapeutic controversy hormone replacement therapy - where are we going? J Clin Endocrinol Metab. 84:1999;1798-1812
130. Rossouw J.E. Estrogens for prevention of coronary heart disease. Putting the brakes on the bandwagon. Circulation. 94:1996;2982-2985
131. Petitti D.B. Hormone replacement therapy and heart disease prevention experimentation trumps observation. JAMA. 280:1998;650-652
132. Heinemann D.F. Osteoporosis. An overview of National Osteoporosis Foundation clinical practice guide. Geriatrics. 55:2002;31-36
133. Solomon C.G., Dluhy R.G. Rethinking postmenopausal hormone therapy. N Engl J Med. 348:2003;579-580
134. Breslau E.S., Davis W.W., Doner L., et al. The hormone therapy dilemma women respond. J Am Med Womens Assoc. 58:2003;33-43
135. Loprinzi C.L., Kugler J.W., Sloan J.A., et al. Venlafaxine in the management of hot flashes in survivors of breast cancer a randomised controlled trial. Lancet. 356:2000;2059-2063
136. Stearns V., Isaacs C., Rowland J., et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol. 11:2000;17-22